Patents by Inventor Wenting Chen

Wenting Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
    Patent number: 7109339
    Abstract: The present invention is directed to novel compounds represented by structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R4a, R5, R6, R7, R8, R9,and m, are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain central nervous system disorders. The compounds of this invention are serotonin receptor modulators, in particular 5HT2C receptor agonists and antagonists, and are useful in the control or prevention of central nervous system disorders including obesity, anorexia, bulemia, depression, anxiety, psychosis, schizophrenia, migraine, addictive behavior, obsessive-compulsive disorder, and sexual disorders.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: September 19, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Taekyu Lee, Wenting Chen, Wei Deng, Albert J. Robichaud, Ruth R. Wexler
  • Substituted heterocyle fused gamma-carbolines
    Publication number: 20060178362
    Abstract: The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
    Type: Application
    Filed: March 15, 2006
    Publication date: August 10, 2006
    Inventors: Albert Robichaud, Taekyu Lee, Wei Deng, Ian Mitchell, Wenting Chen, Christopher McClung, Emilie Calvello, David Zawrotny
  • Substituted heterocycle fused gamma-carbolines
    Patent number: 7081455
    Abstract: The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
    Type: Grant
    Filed: February 25, 2004
    Date of Patent: July 25, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Albert J. Robichaud, Taekyu Lee, Wei Deng, Ian S. Mitchell, Wenting Chen, Christopher D. McClung, Emilie J. Calvello, David M. Zawrotny
  • Substituted heterocycle fused gamma-carbolines
    Publication number: 20060148808
    Abstract: The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
    Type: Application
    Filed: March 14, 2006
    Publication date: July 6, 2006
    Inventors: Albert Robichaud, Taekyu Lee, Wei Deng, Ian Mitchell, Michael Yang, Simon Haydar, Wenting Chen, Christopher McClung, Emilie Calvello, David Zawrotny
  • Substituted heterocycle fused gamma-carbolines
    Patent number: 7071186
    Abstract: The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: July 4, 2006
    Assignee: Bristol-Myers Squibb Pharma Co.
    Inventors: Albert J. Robichaud, Taekyu Lee, Wei Deng, Ian S. Mitchell, Michael G. Yang, Simon Haydar, Wenting Chen, Christopher D. McClung, Emilie J. Calvello, David M. Zawrotny
  • Substituted pyridoindoles as serotonin agonists and antagonists
    Patent number: 6849619
    Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6, R7, R8, R9, X, b, k, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: February 1, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Albert J. Robichaud, John M. Fevig, Ian S. Mitchell, Taekyu Lee, Wenting Chen, Joseph Cacciola
  • Substituted heterocycle fused gamma-carbolines
    Publication number: 20040220178
    Abstract: The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) 1
    Type: Application
    Filed: February 26, 2004
    Publication date: November 4, 2004
    Inventors: Albert J. Robichaud, Taekyu Lee, Wei Deng, Ian S. Mitchell, Michael G. Yang, Simon Haydar, Wenting Chen, Christopher D. McClung, Emilie J. Calvello, David M. Zawrotny
  • Substituted heterocycle fused gamma-carbolines
    Publication number: 20040209864
    Abstract: The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) 1
    Type: Application
    Filed: February 25, 2004
    Publication date: October 21, 2004
    Inventors: Albert J. Robichaud, Taekyu Lee, Wei Deng, Ian S. Mitchell, Wenting Chen, Christopher D. McClung, Emilie J. Calvello, David M. Zawrotny
  • Substituted pyridoindoles as serotonin agonists and antagonists
    Publication number: 20040186094
    Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) 1
    Type: Application
    Filed: February 20, 2004
    Publication date: September 23, 2004
    Inventors: Albert J. Robichaud, John M. Fevig, Ian S. Mitchell, Taekyu Lee, Wenting Chen, Joseph Cacciola
  • Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
    Publication number: 20040180875
    Abstract: The present invention is directed to novel compounds represented by structural Formula (I): 1
    Type: Application
    Filed: December 19, 2003
    Publication date: September 16, 2004
    Inventors: Taekyu Lee, Wenting Chen, Wei Deng, Albert J. Robichaud, Ruth R. Wexler
  • Substituted pyrroloquinolines and pyridoquinolines as serotinin agonists and antagonists
    Patent number: 6777406
    Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein is R1, R6a, R6b, R7, R8, R9, X, b, m, and n are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: August 17, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: John M. Fevig, Ian S. Mitchell, Taekyu Lee, Wenting Chen, Joseph Cacciola
  • Substituted heterocycle fused gamma-carbolines
    Publication number: 20040127482
    Abstract: The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) 1
    Type: Application
    Filed: February 20, 2003
    Publication date: July 1, 2004
    Inventors: Albert J. Robichaud, Taekyu Lee, Wei Deng, Ian S. Mitchell, Wenting Chen, Christopher D. Mc Clung, Emilie J.B. Calvello, David M. Zawrotny
  • SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS
    Publication number: 20040092502
    Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) 1
    Type: Application
    Filed: December 19, 2001
    Publication date: May 13, 2004
    Inventors: John M. Fevig, Ian S. Mitchell, Taekyu Lee, Wenting Chen, Joseph Cacciola
  • Substituted heterocycle fused gamma-carbolines
    Patent number: 6713471
    Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
    Type: Grant
    Filed: June 15, 2000
    Date of Patent: March 30, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Albert J. Robichaud, Taekyu Lee, Wei Deng, Ian S. Mitchell, Simon Haydar, Wenting Chen, Christopher D. Mc Clung, Emilie J. B. Calvello, David M. Zawrotny
  • Substituted pyridoindoles as serotonin agonists and antagonists
    Patent number: 6699852
    Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6, R7, R8, R9, X, b, k, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: March 2, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Albert Robichaud, John M. Fevig, Ian S. Mitchell, Taekyu Lee, Wenting Chen, Joseph Cacciola
  • Substituted heterocycle fused gamma-carbolines
    Publication number: 20040034015
    Abstract: The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) 1
    Type: Application
    Filed: February 20, 2003
    Publication date: February 19, 2004
    Inventors: Albert J. Robichaud, Taekyu Lee, Wei Deng, Ian S. Mitchell, Michael Guang Yang, Simon Haydar, Wenting Chen, Christopher D. MC Clung, Emilie J.B. Calvello, David M. Zawrotny
  • Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands
    Patent number: 6638934
    Abstract: The present invention is directed to novel compounds represented by structural Formulas (I) and (I-a): or a pharmaceutically acceptable salt thereof, wherein R1, R4a, R4b, R5, R6, R7, R8, R9, n, and X are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep and sexual disorders, migraine and other conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: October 28, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Albert Robichaud, Ian S. Mitchell, Taekyu Lee, Wenting Chen
  • Substituted heterocycle fused gamma-carbolines
    Patent number: 6552017
    Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
    Type: Grant
    Filed: June 15, 2000
    Date of Patent: April 22, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Albert J. Robichaud, Taekyu Lee, Wei Deng, Ian S. Mitchell, Michael Guang Yang, Simon Haydar, Wenting Chen, Christopher D. Mc Clung, Emilie J. B. Calvello, David M. Zawrotny
  • Substituted heterocycle fused gamma-carbolines
    Patent number: 6548493
    Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
    Type: Grant
    Filed: June 15, 2000
    Date of Patent: April 15, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Albert J. Robichaud, Taekyu Lee, Wei Deng, Ian S. Mitchell, Wenting Chen, Christopher D. McClung, Emilie J. B. Calvello, David M. Zawrotny
  • Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands
    Publication number: 20020177596
    Abstract: The present invention is directed to novel compounds represented by structural Formulas (I) and (I-a): 1
    Type: Application
    Filed: December 19, 2001
    Publication date: November 28, 2002
    Inventors: Albert Robichaud, Ian S. Mitchell, Taekyu Lee, Wenting Chen